ReviewAdvanced drug delivery reviews2007
shRNA and siRNA delivery to the brain.
Review in Advanced drug delivery reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 175 citations in OpenAlex.
- Associative memory neurons are recruited in PFC-centered circuits to encode schizophrenia-like behavior by dopaminergic receptor-II.Molecular psychiatry · 2026Article
- Auditory cortical neurons are recruited to encode fear signals and anxiety by neuroligin-3-mediated synapse formation.Translational psychiatry · 2025Article
- Associative memory cells of encoding fear signals and anxiety are recruited by neuroligin-3-mediated synapse formation.Communications biology · 2024Article
- Neuroligin-3-Mediated Synapse Formation Strengthens Interactions between Hippocampus and Barrel Cortex in Associative Memory.International journal of molecular sciences · 2024Article
- Article
- Article
- Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Frontiers in cell and developmental biology · 2022Review
- Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.Brain : a journal of neurology · 2021Article
- Design and Development of Nanomaterial-Based Drug Carriers to Overcome the Blood-Brain Barrier by Using Different Transport Mechanisms.International journal of molecular sciences · 2021Review
- Exosomal delivery of therapeutic modulators through the blood-brain barrier; promise and pitfalls.Cell & bioscience · 2021Review
- Multifunctional Gold Nanorod for Therapeutic Applications and Pharmaceutical Delivery Considering Cellular Metabolic Responses, Oxidative Stress and Cellular Longevity.Nanomaterials (Basel, Switzerland) · 2021Review
- Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier.Frontiers in medical technology · 2021Review
- Targeted exosome coating gene-chem nanocomplex as "nanoscavenger" for clearing α-synuclein and immune activation of Parkinson's disease.Science advances · 2020Article
- Nanomedicine for Ischemic Stroke.International journal of molecular sciences · 2020Review
- Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs.Frontiers in neuroscience · 2020Review
- SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer.Theranostics · 2020Article
- RNA delivery biomaterials for the treatment of genetic and rare diseases.Biomaterials · 2019Review
- Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells.Cerebellum (London, England) · 2019Article
- Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells.International journal of nanomedicine · 2019Article
- Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury.Neurobiology of disease · 2018Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The limiting factor in in vivo RNA interference (RNAi) is delivery. Drug delivery methods that are effective in cell culture may not be practical in vivo for intravenous RNAi applications. Nucleic acid drugs are highly charged and do not cross cell membranes by free diffusion. Therefore, the in vivo delivery of RNAi therapeutics must use targeting technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. For RNAi of the brain, the nucleic acid-based drug must first cross the brain capillary endothelial wall, which forms the blood-brain barrier (BBB) in vivo, and then traverses the brain cell plasma membrane. Similar to the delivery of non-viral gene therapies, plasmid DNA encoding for short hairpin RNA (shRNA) may be delivered to the brain following intravenous administration with pegylated immunoliposomes (PILs). The plasmid DNA is encapsulated in a 100 nm liposome, which is pegylated, and conjugated with receptor specific targeting monoclonal antibodies (MAb). Weekly, intravenous RNAi with PILs enables a 90% knockdown of the human epidermal growth factor receptor, which results in a 90% increase in survival time in mice with intra-cranial brain cancer. Similar to the delivery of antisense agents, short interfering RNAi (siRNA) duplexes can be delivered with the combined use of targeting MAb's and avidin-biotin technology. The siRNA is mono-biotinylated in parallel with the production of a conjugate of the targeting MAb and streptavidin. Intravenous RNAi requires the combined use of RNAi technology and a drug targeting technology that is effective in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.